{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hickey CJ"],"funding":["European Hematology Association","NCI NIH HHS"],"pagination":["159-69"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3538328"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["121(1)"],"pubmed_abstract":["Recently, we showed that increased miR-181a expression was associated with improved outcomes in cytogenetically normal acute myeloid leukemia (CN-AML). Interestingly, miR-181a expression was increased in CN-AML patients harboring CEBPA mutations, which are usually biallelic and associate with better prognosis. CEBPA encodes the C/EBPα transcription factor. We demonstrate here that the presence of N-terminal CEBPA mutations and miR-181a expression are linked. Indeed, the truncated C/EBPα-p30 isoform, which is produced from the N-terminal mutant CEBPA gene or from the differential translation of wild-type CEBPA mRNA and is commonly believed to have no transactivation activity, binds to the miR-181a-1 promoter and up-regulates the microRNA expression. Furthermore, we show that lenalidomide, a"],"journal":["Blood"],"pubmed_title":["Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia."],"pmcid":["PMC3538328"],"funding_grant_id":["CA35279","CA101140","U10 CA035279","U24 CA114725","CA114725","CA16058","CA33601","U10 CA003927","CA31946","U10 CA031946","P30 CA016058","U10 CA077658","U10 CA101140","TRTH68","CA03927","CA41287","CA77658","R01 CA095512","U10 CA033601","U10 CA041287","P50 CA140158"],"pubmed_authors":["Vij R","Whitman SP","Becker H","Santhanam R","Zhao X","Mrozek K","Nicolet D","Perrotti D","Radomska HS","Walker A","Bloomfield CD","Fehniger TA","Byrd JC","Lee LJ","Marcucci G","Alachkar H","Eiring AM","Maharry K","Wu LC","Hickey CJ","Schwind S","Garzon R","Blum W","Mishra A","Dorrance AM","Wu YZ","Caligiuri MA"],"additional_accession":[]},"is_claimable":false,"name":"Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.","description":"Recently, we showed that increased miR-181a expression was associated with improved outcomes in cytogenetically normal acute myeloid leukemia (CN-AML). Interestingly, miR-181a expression was increased in CN-AML patients harboring CEBPA mutations, which are usually biallelic and associate with better prognosis. CEBPA encodes the C/EBPα transcription factor. We demonstrate here that the presence of N-terminal CEBPA mutations and miR-181a expression are linked. Indeed, the truncated C/EBPα-p30 isoform, which is produced from the N-terminal mutant CEBPA gene or from the differential translation of wild-type CEBPA mRNA and is commonly believed to have no transactivation activity, binds to the miR-181a-1 promoter and up-regulates the microRNA expression. Furthermore, we show that lenalidomide, a","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Jan","modification":"2026-05-02T09:11:42.839Z","creation":"2026-04-07T17:47:39.408Z"},"accession":"S-EPMC3538328","cross_references":{"pubmed":["23100311"],"doi":["10.1182/blood-2012-05-428573"]}}